Recombinant NDV Vaccine Expressing Truncated Fiber 2 Protein
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for Angraradisease and Newcastle Disease have limitations, including lack of thermal stability and dual protection, making them unsuitable for tropical and remote areas and failing to address the dual threat posed by these diseases effectively.
Innovation Solution
A heat-resistant recombinant Newcastle Disease Virus (NDV) vaccine strain, rLS-tFib2-C, is developed through reverse genetic manipulation by replacing the HN gene and inserting truncated Fiber 2 gene of Fowl Adenovirus serotype 4, enhancing thermal stability and providing dual protection against Angraradisease and Newcastle Disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If LaSota strain vaccine is used for Newcastle Disease prevention, then immunogenicity and immune protection rate are improved, but thermal stability deteriorates requiring strict cold chain
Solution Approach 1:
The patent combines two separate vaccine functions into a single recombinant virus platform. The NDV LaSota strain serves as the vector platform, merging the Newcastle Disease antigen expression capability with the FAdV-4 Fiber2 protein expression capability, creating a dual-protection vaccine that addresses both diseases simultaneously
Solution Approach 2:
The patent modifies the viral vector parameters by replacing the HN gene and inserting the FAdV-4 Fiber2 gene into the NDV LaSota strain. This genetic parameter change transforms the vaccine from providing only ND protection to providing dual protection against both ND and Angrara disease, while improving thermal stability
2Adaptability or versatility
If separate vaccines for Angraradisease and Newcastle Disease are used, then disease coverage is improved, but device complexity and immunization procedures deteriorate
Solution Approach 1:
The recombinant NDV vaccine achieves multi-functionality by simultaneously providing protection against two different diseases (Newcastle Disease and Angrara disease). The single vaccine formulation expresses both NDV antigens and FAdV-4 Fiber2 protein, eliminating the need for separate vaccine administrations and simplifying the immunization system
Solution Approach 2:
The patent merges two separate vaccine programs into one unified vaccine solution. By co-expressing NDV structural proteins and FAdV-4 Fiber2 protein in the same recombinant virus, the patent combines the functionality of two distinct vaccines into a single administration system
3Reliability
If traditional vaccine strategies are used for tropical and remote areas, then current vaccine limitations are maintained, but ease of operation and promotion deteriorate due to cold chain requirements
Solution Approach 1:
The patent changes the thermal stability parameter of the vaccine by using the NDV LaSota strain as a platform, which inherently possesses better thermal stability compared to traditional FAdV vaccines. This parameter change enables the vaccine to maintain effectiveness in tropical and remote areas without requiring strict cold chain infrastructure
Data Source
AI summary
A heat-resistant recombinant Newcastle Disease Virus vaccine strain rLS-tFib2-C capable of expressing truncated Fiber 2 protein of fowl adenovirus serotype 4 has been preserved at the China Center for Type Culture Collection, Wuhan University, Wuhan, China with the preservation number of CCTCC No. V202042.